Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib + Nivolumab in Advanced Clear Cell RCC
NCT03015740Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2017
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitravatinib in clear cell renal cell carcinoma (ccRCC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2017; status: completed.
02
Drugs
sitravatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03015740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015740.